GLENMARK
Brokerage: Morgan Stanley
Rating: OVERWEIGHT
Target: Rs 534
Rationale: Srong earnings driven by growth in attractive markets like Bazil and Russia, lucrative therapies and focus on niche opportunities in the US. They have a target of 534 on the stock.